High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: An "Intergruppo Italiano Linfomi" randomized trial

Haematologica

Volumn 90, Issue 6, 2005, Pages 793-801

  Vitolo, Umberto ^a   Liberati, Anna Marina ^b   Cabras, Maria Giuseppina ^c   Federico, Massimo ^d   Angelucci, Emanuele ^c   Baldini, Luca ^e   Boccomini, Carola ^a   Brugiatelli, Maura ^f   Calvi, Roberta ^a   Ciccone, Giovannino ^a   Genua, Angelo ^b   Deliliers, Giorgio Lambertenghi ^e   Levis, Alessandro ^g   Parvis, Guido ^h   Pavone, Enzo ⁱ   Salvi, Ravia ^g   Sborgia, Marco ^j   Gallo, Eugenio ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Divisione Medicina Interna   (Italy)

^c Ospedale Oncologico A Businco   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f Azienda Ospedaliera Papardo   (Italy)

^g C Arrigo Children's Hospital   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j Ematologia Clinica   (Italy)

more..

Author keywords

Autologous transplantation; Dose dense chemotherapy; Poor prognosis DLCL

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BACTERIAL PNEUMONIA; BLOOD TOXICITY; BONE MARROW METASTASIS; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; ITALY; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LUNG ASPERGILLOSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NEUTROPENIA; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE; TUMOR VOLUME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, LARGE-CELL; MALE; MELPHALAN; MIDDLE AGED; MITOXANTRONE; PREDNISONE; PROGNOSIS; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 21244501697     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Coltman AC Jr, Dahlberg S, Jones ES, et al. CHOP is curative in thirty per cent of patients with large cell lymphoma: a twelve year Southwest Oncology Group follow-up, in Skarin AT, Editor. Advances in Cancer Chemotherapy: Update on Treatment for Diffuse Large Cell Lymphoma. New York, NY; Park Row 1986. p. 71-7.
2. Fisher RI, Gaynor ER, Dahlberg R, Oken MM, Grogan TM, Mize EM, et al. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
3. Shipp MA, Harrington DP. A predictive model for aggressive NHL: the International Non-Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med 1993;329:987-94.
4. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
5. Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, et al. Intensified and high dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997;15:491-8.
6. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-7.
7. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non Hodgkin's lymphoma: results of a prospective randomized trial by the non Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:2796-802.
8. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high dose therapy in poor risk non Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol, a groupe d'Etude des lymhomes de l'Adulte study. J Clin Oncol 2000;18:3025-30.
9. Milpied N, Decorininck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. N Engl J Med 2004;350:1287-95.
10. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high dose chemotherapy for patients with poor-prognosis aggressive lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2002;20:2472-9.
11. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995;13:2916-23
12. Tilly H, Mounier N, Lederlin P, Briere J, Dupriez B, Sebban C, et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. J Clin Oncol 2000; 18:1309-15.
13. Talbot SM, Westerman DA, Grigg AP, Toner GC, Wolf M, Bishop J, et al. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicine in patients with non-Hodgkin's lymphoma and advanced solid tumors. Ann Oncol 1999;10:907-14.
14. Vitolo U, Botto B, Boccomini C. Intensified chemotherapy with dose intensity escalation or cyclophosphamide and epirubicin with filgrastim support (MegaCEOP) for poor prognosis aggressive non-Hodgkin's lymphoma. Blood 1997;90 Suppl 1: 190a[Abstract].
15. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
16. Vitolo U, Bertini M, Brusamolino E, Cavallero GB, Comotti B, Gallo E, et al. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992;10: 219-27.
17. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-22.
18. Cheson BD, Horning SJ, Coiffier B. Report of an International Workshop to standardize response criteria for non Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-53.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete information. J Am Stat Assoc 1958;53:547-81.
20. Cox DR. Regression model and life tables (with discussion). JR Stat Soc 1972;34:187-222.
21. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy a spart of primary treatment for "Aggressive" lIymphoma. J Clin Oncol 2002; 20:4413-9.
22. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomised trial. J Clin Oncol 2003;21: 1255-62.
23. Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, et al. Dose intense, every two week chemotherapy (CHOP-DI) may improve survival in intermediate and high grade lymphoma. The Southwest Oncology Group. J Clin Oncol 2003;21:2466-73.
24. Balzarotti M, Spina M, Sarina B, Magagnoli M, Castagna L, Milan I, et al. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicine and cyclophosphamide. Ann Oncol 2002;13:1341-6.
25. Meyer RM, Quirt IC, Skillings JR, Cripps MC, Bramwell VH, Weinerman BH, et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkins lymphoma. N Engl J Med 1993;329:1770-6.
26. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. Blood 2003;102:4284-9.
27. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33.
28. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP Chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. German High-Grade Non-Hodgkin's Lymphoma Study Group. Blood 2004;104:634-41.
29. Milligan DW, Ruiz De Elvira MC, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ, et al. Secondary leukemia and myelodisplasia after autografting for lymphoma: results from the EBMT lymphoma and late effects working parties. B J Haematol 1999;106:1020-6.
30. Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP plus Rituximab with CHOP chemotherapy in elderly patients with diffuse large B-cell lymphoma: a Group d'Etude des Lymphomes de l'Adulte study. N Engl J Med 2002; 346:235-42.
31. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo purged stem cell autografting (R-HDS regimen). Blood 2003;102:749-55.
32. Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003;88: 1304-15.
33. Mounier N, Gisselbrecht C, Brière J, Haioun C, Feugier P, Offner F, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysys by the Groupe d'Etude des lymhomes de l'Adulte (GELA). Ann Oncol 2004;15:1790-7.